Hormonal
In the presence of a high-fat diet, fructose supplementation causes pronounced obesity, glucose intolerance, and hepatic insulin resistance, whereas glucose supplementation does not cause these metabolic deficits despite similar caloric intake.
If you are eating a high-fat diet, the type of sugar you consume matters significantly. Fructose (found in high-fructose corn syrup and table sugar) promotes obesity and insulin resistance, whereas glucose does not have the same negative impact on insulin signaling under these conditions. To mitigate metabolic risk, prioritize reducing fructose intake, especially when dietary fat is high.
mice on HFD supplemented with fructose developed more pronounced obesity, glucose intolerance, and hepatomegaly as compared to glucose-supplemented HFD mice, despite similar caloric intake.
Why this rating
High-quality controlled animal study with human validation of biomarkers, though not a direct human clinical trial for the intervention.
Source
Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling
Samir Softic et al. · Journal of Clinical Investigation · 2017
DOI 10.1172/jci94585
More from this paper
- Fructose uniquely upregulates the transcription factor SREBP1c and downstream fatty acid synthesis genes, leading to reduced liver insulin signaling, whereas glucose upregulates ChREBP and triglyceride synthesis without impairing insulin signaling.Good
- Knocking down Ketohexokinase (KHK), the first enzyme in fructose metabolism, improves hepatic steatosis and glucose tolerance in fructose-supplemented mice.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →